Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junlin Li

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Cancer Medicine|July 6, 2024
Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective studyYuekun Wang, Hao Xing, Xiaopeng Guo, et al.
Cancer Medicine|September 5, 2023
Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumorsWenlin Chen, Siying Guo, Yaning Wang, et al.
Frontiers in Oncology|March 31, 2023
Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumorsXiaopeng Guo, Yixin Shi, Delin Liu, et al.
Frontiers in Neuroscience|May 22, 2023
Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumorsWenlin Chen, Shanmu Jin, Qianshu Liu, et al.
Discover Oncology|March 22, 2024
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapyShanmu Jin, Wenlin Chen, Xiaopeng Guo, et al.
Cancer Medicine|January 13, 2025
TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World StudyHao Xing, Delin Liu, Junlin Li, et al.
Frontiers in Oncology|July 24, 2023
Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsXiaopeng Guo, Lingui Gu, Yilin Li, et al.
Frontiers in Neuroscience|April 10, 2024
Clinical roles of <i>EGFR</i> amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumorsHai Wang, Xin Zhang, Jiahui Liu, et al.
BMC Neurology|June 14, 2024
The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysisYixin Shi, Xiaoman Kang, Yulu Ge, et al.
Journal of Molecular Neuroscience : MN|February 5, 2024
Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO ClassificationKun Zhang, Tianrui Yang, Yu Xia, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Cancer Medicine|July 6, 2024
Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective studyYuekun Wang, Hao Xing, Xiaopeng Guo, et al.
Cancer Medicine|September 5, 2023
Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumorsWenlin Chen, Siying Guo, Yaning Wang, et al.
Frontiers in Oncology|March 31, 2023
Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumorsXiaopeng Guo, Yixin Shi, Delin Liu, et al.
Frontiers in Neuroscience|May 22, 2023
Spotlights on adult patients with pediatric-type diffuse gliomas in accordance with the 2021 WHO classification of CNS tumorsWenlin Chen, Shanmu Jin, Qianshu Liu, et al.
Discover Oncology|March 22, 2024
A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapyShanmu Jin, Wenlin Chen, Xiaopeng Guo, et al.
Cancer Medicine|January 13, 2025
TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World StudyHao Xing, Delin Liu, Junlin Li, et al.
Frontiers in Oncology|July 24, 2023
Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsXiaopeng Guo, Lingui Gu, Yilin Li, et al.
Frontiers in Neuroscience|April 10, 2024
Clinical roles of <i>EGFR</i> amplification in diffuse gliomas: a real-world study using the 2021 WHO classification of CNS tumorsHai Wang, Xin Zhang, Jiahui Liu, et al.
BMC Neurology|June 14, 2024
The molecular signature and prognosis of glioma with preoperative intratumoral hemorrhage: a retrospective cohort analysisYixin Shi, Xiaoman Kang, Yulu Ge, et al.
Journal of Molecular Neuroscience : MN|February 5, 2024
Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO ClassificationKun Zhang, Tianrui Yang, Yu Xia, et al.
Pageof 17